學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
BGI Genomics: Strategic Corporate Social Responsibility
內容大綱
BGI Genomics (BGI), founded in China in 1999, covered the entire field of genomic sequencing applications. During the COVID-19 pandemic in 2020, BGI's strategic corporate social responsibility initiative, developing coronavirus nucleic acid test kits, created shared value for BGI and society; brought revenue growth to the company; and won BGI acclamation from the government, media, and public. However, as the market competition in the COVID-19 testing business intensified, Zhao Lijian, chief executive officer of BGI, had to consider the company's next direction: Should BGI significantly increase investment in the COVID-19 testing business and shoulder greater social responsibility for fighting the pandemic? Or should it shift the focus back to its main business?